Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology-Reference-Cited by-同舟云学术

Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

Published:2024-04-05 Issue:6 Volume:29 Page:689-699
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Ito Mamoru,Okumura Yuta,Nio Kenta,Baba Eishi,Ozaki Yukinori,Nishio Hiroshi,Ichihara Eiki,Miura Yuji,Endo Makoto,Yano Shingo,Maruyama Dai,Yoshinami Tetsuhiro,Susumu Nobuyuki,Takekuma Munetaka,Motohashi Takashi,Ochi Nobuaki,Kubo Toshio,Uchino Keita,Kimura Takahiro,Kamiyama Yutaro,Nakao Shinji,Tamura Shinobu,Nishimoto Hitomi,Kato Yasuhisa,Sato Atsushi,Takano Toshimi,Tsuchihashi Kenji^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02502-6.pdf

Reference34 articles.

1. Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/stat/summary.html. Accessed 29 Jan 2024

2. Del Mastro L, De Placido S, Bruzzi P et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385:1863–1872. https://doi.org/10.1016/S0140-6736(14)62048-1

3. The Japan Society of Clinical Oncology (2022) Clinical Practice Guidelines for the Use of G-CSF. KANEHARA & CO., LTD.

4. Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199–3212. https://doi.org/10.1200/JCO.2015.62.3488

5. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32. https://doi.org/10.1016/j.ejca.2010.10.013